Edgewise Therapeutics initiates EDG-7500 Phase 1 trial targeting cardiac diseases
Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a biopharmaceutical company specializing in muscle diseases, announced the commencement of its Phase 1 trial for EDG-7500. This oral, selective, cardiac sarcomere modulator targets diastolic dysfunction and diseases like hypertrophic cardiomyopathy (HCM). The randomized, double-blind, placebo-controlled trial will evaluate EDG-7500’s safety and pharmacokinetics in healthy adults. A Phase 1b study […]